Zacks: Brokerages Anticipate argenx SE – (NASDAQ:ARGX) Will Announce Quarterly Sales of $25.00 Million

Wall Street brokerages expect argenx SE – (NASDAQ:ARGX) to announce $25.00 million in sales for the current fiscal quarter, according to Zacks Investment Research. Three analysts have provided estimates for argenx’s earnings, with the highest sales estimate coming in at $42.56 million and the lowest estimate coming in at $10.17 million. The firm is expected to report its next quarterly earnings report on Monday, January 1st.

On average, analysts expect that argenx will report full year sales of $79.91 million for the current financial year, with estimates ranging from $57.68 million to $114.00 million. For the next financial year, analysts expect that the business will report sales of $53.07 million, with estimates ranging from $28.03 million to $92.82 million. Zacks’ sales averages are an average based on a survey of analysts that cover argenx.

Several equities research analysts have recently weighed in on the company. Wedbush upped their price objective on argenx from $131.00 to $144.00 and gave the company an “outperform” rating in a research note on Friday, March 1st. Zacks Investment Research lowered argenx from a “hold” rating to a “sell” rating in a research note on Tuesday, March 5th. Stifel Nicolaus set a $154.00 price objective on argenx and gave the company a “buy” rating in a research note on Wednesday, May 22nd. Piper Jaffray Companies upped their price objective on argenx from $161.00 to $182.00 and gave the company an “overweight” rating in a research note on Thursday, May 23rd. Finally, Guggenheim assumed coverage on argenx in a research note on Friday, February 22nd. They issued a “buy” rating and a $157.00 price objective on the stock. One equities research analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $147.36.

Shares of ARGX stock traded up $2.35 during trading hours on Friday, hitting $122.13. The company had a trading volume of 7,834 shares, compared to its average volume of 194,255. argenx has a 12 month low of $63.81 and a 12 month high of $137.50. The firm has a market cap of $3.85 billion, a P/E ratio of -51.97 and a beta of 1.22.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. JGP Global Gestao de Recursos Ltda. boosted its position in argenx by 9.0% in the 1st quarter. JGP Global Gestao de Recursos Ltda. now owns 2,288 shares of the company’s stock valued at $286,000 after buying an additional 188 shares during the last quarter. Dorsey Wright & Associates lifted its stake in shares of argenx by 0.4% in the 1st quarter. Dorsey Wright & Associates now owns 46,946 shares of the company’s stock valued at $5,861,000 after purchasing an additional 209 shares during the period. Dimensional Fund Advisors LP lifted its stake in shares of argenx by 4.1% in the 1st quarter. Dimensional Fund Advisors LP now owns 9,450 shares of the company’s stock valued at $1,180,000 after purchasing an additional 376 shares during the period. Northern Trust Corp lifted its stake in shares of argenx by 2.7% in the 1st quarter. Northern Trust Corp now owns 15,820 shares of the company’s stock valued at $1,975,000 after purchasing an additional 418 shares during the period. Finally, Marshall Wace LLP acquired a new position in shares of argenx in the 1st quarter valued at $121,000. Hedge funds and other institutional investors own 68.09% of the company’s stock.

About argenx

argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's lead product candidates include ARGX-113 that completed Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis, immune thrombocytopenia, and pemphigus vulgaris; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome.

Featured Story: Google Finance Portfolio

Get a free copy of the Zacks research report on argenx (ARGX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for argenx (NASDAQ:ARGX)

Receive News & Ratings for argenx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenx and related companies with MarketBeat.com's FREE daily email newsletter.